Revance’s leadership is committed to setting the new standard in healthcare and has deep experience commercializing products in highly competitive markets. As a group, we represent more than a century of experience launching innovative products that change people’s lives. We believe in leaving bureaucracy behind and value speed, authenticity, audacity, grit and empathy.
For customer service, product information, new accounts or adverse events call: 877-3REV-NOW
For all other inquires call: +1 (510) 742-3400
1222 Demonbreun St
20th Floor
Nashville, TN 37203
Mark Foley is CEO of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors of Glaukos (GKOS) and as chairman of the board for ULab. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame in 1987 and is a named inventor on 17 patent applications.
Dustin S. Sjuts is President of Revance Therapeutics. An accomplished executive bringing more than 20 years of cross-functional leadership, Mr. Sjuts has extensive experience fueling the global adoption of innovative products in the biotechnology, medical device, pharmaceutical, and healthcare technology fields. Prior to Revance, Mr. Sjuts held leadership positions at Nestle Skin Health, including Business Unit Head, China, and Senior Director of Marketing. Previously, Mr. Sjuts held positions of increasing responsibility across a range of markets and disciplines with Alphaeon and Allergan. He was responsible for creating and executing strategies that drove award-winning commercial success, including new product adoption and competitive sales growth. Mr. Sjuts holds a B.A.Sc. from Illinois State University.
Tobin C. Schilke joined Revance as Chief Financial Officer in November of 2018. He brings more than 20 years’ experience in the global biopharma arena, raising capital, completing mergers and acquisitions (M&A) and providing financial leadership in support of commercial enterprises. From 2016 to 2018 Mr. Schilke served as Chief Financial Officer at Achaogen, Inc., where he raised more than $300 million in capital and built teams and capabilities in financial planning and analysis (FP&A), accounting, procurement, IT and facilities management. Previously, he spent 13 years at Roche/Genentech in a variety of finance and operational roles including CFO of Roche Products Limited in the United Kingdom, Director of Commercial FP&A for Genentech’s BioOncology business, and M&A project manager for a number of successful acquisitions, restructurings, and business development initiatives. Mr. Schilke holds a B.S. in Chemical Engineering from Lafayette College, M.S. in Chemical Engineering from University of California, Berkeley, and an M.B.A. from Cornell University.
Dwight Moxie joined Revance in 2020 as Corporate Secretary to the Board and as Senior Vice President, General Counsel & Corporate Secretary on the Senior Executive Team. Mr. Moxie leads all legal, governance, and compliance initiatives for Revance.
Mr. Moxie brings extensive legal experience in the biopharma and healthcare sectors, advising and supporting companies developing and commercializing novel drugs. Prior to Revance, he served as the Vice President, Deputy General Counsel at Ultragenyx where he oversaw commercial operations, litigation, research & development and regulatory matters. In this position, Mr. Moxie advised on pharmaceutical education and product marketing activities, including DTC advertisements, improved review systems to support product launches and counseled on matters including clinical trials, labeling and more. Prior to Ultragenyx, he served in various legal counsel positions at Allergan and GlaxoSmithKline.
Mr. Moxie holds a J.D. degree from Howard University School of Law and a Bachelor of Arts in Social Science from Florida State University.
Chief Medical Officer
David A. Hollander, M.D., M.B.A., joined Revance in October 2022 as Chief Medical Officer, overseeing clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.
Dr. Hollander brings over 20 years of experience in the global biotech and pharma industry, spanning the entire drug development life cycle. Prior to joining Revance, he was the Chief Research & Development Officer at Aerie Pharmaceuticals, where he directed preclinical research and clinical development in the U.S., Europe and Japan, and led the company’s medical affairs, regulatory and quality organizations. Previously, he was the Chief Medical Officer at Ora, Inc., where he oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints. Dr. Hollander began his industry career at Allergan, Inc., where he spent a decade serving in roles of increasing responsibility, including Vice President, Global Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. Dr. Hollander currently serves as a Board Member for Kiora Pharmaceuticals and the Arnold & Mabel Beckman Foundation.
Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, earned his medical degree at the University of Pennsylvania School of Medicine, and obtained an M.B.A. in Health Care Management from the Wharton School. He completed his residency in ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External Disease, and Refractive Surgery at the Jules Stein Eye Institute, University of California, Los Angeles.
Justin Ford joined Revance in June of 2017, bringing more than 30 years’ experience building, developing, and aligning organizational and cultural capabilities to impact profitability, growth, business priorities and employee engagement. He came to Revance from Raptor Pharmaceuticals, a rare disease biopharmaceutical company (acquired by Horizon Pharma), where he was Senior Vice President of Human Resources. Prior to Raptor, he served as Global VP of HR and Administration at Micromet, Inc. and as Global VP, HR with Bayer Pharmaceuticals. Mr. Ford also held Human Resources leadership positions at Monsanto, Givaudan, Washington University in St. Louis, Engelhard (BASF), and Newport News Shipbuilding. He earned a B.A. in Human Resources from The University of Kansas, is a Certified Compensation Professional, and has completed the curriculum and taught at the Advanced Program in Human Resource Management at The John Anderson Graduate School of Management at UCLA.
Azita Nejad joined Revance in 2014. Ms. Nejad brings to Revance more than 28 years of experience of cross-functional leadership as well as CMC, with an in-depth knowledge of quality for both clinical development and commercial products in various dosage forms. Prior to Revance, Ms. Nejad held quality leadership positions at Gilead Sciences, and was involved in several submissions, regulatory inspections and/or approvals, including Sovaldi®, Stribild® and Complera®. Additionally, Ms. Nejad has held several positions of increasing responsibility in quality assurance and control with CV Therapeutics, Nektar Therapeutics and Spectrum Medical Industries. She also supported the approval and commercial launch of several other marketed products such as Ranexa® and Lexiscan®. Ms. Nejad holds a B.S. in Chemistry from University of Colorado.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
